The Diagnostic Value of ACSL1, ACSL4, and ACSL5 and the Clinical Potential of an ACSL Inhibitor in Non-Small-Cell...

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Abnormal expression of Acyl-CoA synthetase long-chain (ACSL) members is common in human cancers, but their specific roles and clinical significance in lung cancer remain largely unelucidated.
• ACSLs are crucial enzymes involved in fatty acid metabolism, a process increasingly recognized for its role in cancer progression and drug resistance.

Purpose of the Study:

• To investigate the expression patterns of ACSL family members (ACSL1, ACSL3, ACSL4, ACSL5, and ACSL6) in lung cancer.
• To evaluate the therapeutic potential of the ACSL inhibitor Triacsin C (TC) in combination with standard lung cancer treatments.

Main Methods:

• Analysis of ACSL gene expression in lung cancer cell lines and primary tumors compared to normal bronchial epithelial cells.
• Assessment of ACSL activity and its correlation with ACSL expression levels.
• Investigation of the effects of Triacsin C alone and in combination with Gemcitabine or EGFR-TKIs on lung cancer cell growth and drug sensitivity.

Main Results:

• ACSL1, ACSL4, and ACSL6 were upregulated, while ACSL3 and ACSL5 were downregulated in most lung cancer cell lines compared to normal cells.
• Higher expression of ACSL1, ACSL4, and ACSL5 correlated with adenocarcinoma (ADC).
• ACSL5 expression inversely correlated with Ki67 in low-grade tumors, while ACSL3 positively correlated with Ki67 in high-grade tumors, suggesting roles in differentiation.
• Combination therapy of TC with Gemcitabine enhanced growth inhibition in EGFR wild-type cells.
• TC sensitized EGFR-mutant cells to EGFR-TKIs, potentially overcoming resistance.

Conclusions:

• ACSL1 may serve as a diagnostic biomarker for lung adenocarcinoma.
• ACSL1, ACSL4, and ACSL5 appear to be involved in the differentiation of lung tumors.
• Triacsin C, as an ACSL inhibitor, demonstrates promise for combination therapy to enhance efficacy and overcome drug resistance in lung cancer, particularly with chemotherapy or EGFR-targeted agents.